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OBJECTIVE—This study sought to investigate an association of
HbA1c (A1C) with incident heart failure among individuals
without diabetes and compare it to fasting glucose.
RESEARCH DESIGN AND METHODS—We studied 11,057
participants of the Atherosclerosis Risk in Communities (ARIC)
Study without heart failure or diabetes at baseline and estimated
hazard ratios of incident heart failure by categories of A1C (5.0,
5.0–5.4 [reference], 5.5–5.9, and 6.0–6.4%) and fasting glucose
(90, 90–99 [reference], 100–109, and 110–125 mg/dl) using Cox
proportional hazards models.
RESULTS—A total of 841 cases of incident heart failure hospi-
talization or deaths (International Classiﬁcation of Disease,
9th/10th Revision, 428/I50) occurred during a median follow-up
of 14.1 years (incidence rate 5.7 per 1,000 person-years). After the
adjustment for covariates including fasting glucose, the hazard
ratio of incident heart failure was higher in individuals with A1C
6.0–6.4% (1.40 [95% CI, 1.09–1.79]) and 5.5–6.0% (1.16 [0.98–
1.37]) as compared with the reference group. Similar results were
observed when adjusting for insulin level or limiting to heart
failure cases without preceding coronary events or developed
diabetes during follow-up. In contrast, elevated fasting glucose
was not associated with heart failure after adjustment for covari-
ates and A1C. Similar ﬁndings were observed when the top
quartile (A1C, 5.7–6.4%, and fasting glucose, 108–125 mg/dl) was
compared with the lowest quartile (5.2% and 95 mg/dl,
respectively).
CONCLUSIONS—Elevated A1C (5.5–6.0%) was associated
with incident heart failure in a middle-aged population without
diabetes, suggesting that chronic hyperglycemia prior to the
development of diabetes contributes to development of heart
failure. Diabetes 59:2020–2026, 2010
D
iabetes is one of the most important risk factors
for heart failure (1). Among people with diabe-
tes, a dose relationship between glycemia mea-
sured by HbA1c (A1C) and heart failure risk has
been reported in observational studies (1–6). The risk of
hospitalization for heart failure increases 8–32% per 1%
unit increase in A1C (3–6).
In contrast, to our knowledge, no previous study has
investigated the association between A1C and the risk of
heart failure in a population without diabetes. In this
population, fasting glucose is only marginally or not asso-
ciated with heart failure risk (7,8). This may be partially
attributable to relatively high variability in glucose mea-
surements (9) and to the fact that fasting glucose levels do
not necessarily reﬂect postprandial hyperglycemia, a con-
dition potentially contributing to development of cardio-
vascular disease (10,11).
In January 2010, the American Diabetes Association
published new clinical guidelines recommending the use
of A1C as a diagnostic test for diabetes (12), with cut-
points based largely on the documented association of
A1C with microvascular disease. Little is known, however,
regarding the risk relationship of A1C levels with heart
failure incidence in nondiabetic adults. The objective of
this study was to investigate a possible relationship be-
tween A1C and the incidence of heart failure in a commu-
nity-based study of people without diabetes. We also
compared the associations of A1C and fasting glucose
levels with risk of incident heart failure in this middle-aged
nondiabetic population.
RESEARCH DESIGN AND METHODS
The Atherosclerosis Risk in Communities (ARIC) Study is a community-based
cohort study of 15,792 people aged 45–64 years at baseline sampled from four
U.S. communities: Forsyth County, North Carolina; suburban Minneapolis,
Minnesota; Washington County, Maryland; and Jackson, Mississippi (13). The
ﬁrst examination was conducted during 1987–1989, with three triennial
follow-up visits (visit 2 (1990–1992), visit 3 (1993–1995), and visit 4 (1996–
1998)). Visit 2 was the only visit at which A1C was measured and was the
baseline for the present study. There were 14,348 participants (91.4%) who
attended visit 2. Of these, we excluded participants reporting race other than
Caucasian or African American (n  42); missing values of A1C (n  278);
with prevalent heart failure deﬁned as self-reported treatment for heart
failure, hospitalization for heart failure between visit 1 and 2, or the Gothen-
burg stage 3, a status with dyspnea due to cardiac causes and under treatment
with digitalis or loop diuretics (n  455) (14,15); or missing information about
incident heart failure during follow-up (n  245). We also excluded partici-
pants with diabetes deﬁned by a fasting glucose of 7.0 mmol/l (126 mg/dl),
nonfasting glucose of 11.1 mmol/l (200 mg/dl), A1C 6.5% (12), self-
reported physician diagnosis of diabetes, or use of glucose-lowering medica-
tion (n  2,174) or missing information for diabetes (n  97) at either of visit
1 or visit 2, for a ﬁnal study population size of 11,057 participants. The study
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Data collection. ARIC study participants provided information on demographic
and behavioral variables and medical history to a trained interviewer at each visit.
In this study, we used information obtained at visit 2, unless otherwise noted.
Smoking status and alcohol intake were determined by self-report. Participants
were asked to bring all medications, which were coded by trained personnel.
Information about completed years of education was obtained at visit 1. Certiﬁed
technicians measured three systolic and diastolic blood pressures with partici-
pants in the sitting position after 5 min of rest using a random-zero sphygmoma-
nometer. The average of the second and third readings was recorded. A1C was
measured using a high-performance liquid chromatography instrument (Tosoh
2.2 Plus in 2003–2004 and the Tosoh G7 in 2007–2008, Tosoh Corporation, Tokyo,
Japan) on all participants with available stored whole blood (16). We have
previously demonstrated the reliability of measurements from these stored
samples (17). Fasting serum glucose was measured by the optimized DART
GLUCOSE reagent method and cholesterol, triglycerides, and HDL cholesterol
were determined using enzymatic methods. LDL cholesterol was calculated using
the Friedewald equation (18). Insulin was measured by radioimmunoassay
(125Insulin kit; Cambridge Medical Diagnosis, Bilerica, MA) at visit 1 (19). Serum
creatinine concentration was measured using a modiﬁed kinetic Jaffe method.
Estimated glomerular ﬁltration rate was computed by the Modiﬁcation of Diet in
Renal Disease Study equation (20). Evidence of atherosclerosis of the common
carotid arteries (shadowing/plaque on either side or none) was determined by
ultrasound examination (13,21).
Outcome. ARIC investigators conduct continuous, comprehensive surveil-
lance for all cardiovascular disease-related hospitalizations and deaths in the
four communities. Incident heart failure was deﬁned as death from heart
failure in any position on the death certiﬁcate or as the ﬁrst heart failure
hospitalization with the International Classiﬁcation of Diseases Code, Ninth
Revision (ICD-9) 428 or Tenth Revision (ICD-10) I50 in any position of the
hospital discharge list (6). Incident heart failure from visit 2 to January 1, 2006,
was analyzed in the present study.
Statistical analyses. We categorized A1C using the following cut-points: 5.0,
5.0–5.4, 5.5–5.9, and 6.0–6.4%. Baseline characteristics of the population were
compared across these A1C categories. We evaluated the continuous association
between A1C and the incidence rates of heart failure using a Poisson regression
model incorporating linear spline terms for A1C (knots at 5.0, 5.5, and 6.0%) with
adjustment for age, sex, and race. Cox proportional hazards models were used to
quantify the association between the above categories of A1C and incident heart
failure. We tested for interactions using the likelihood-ratio test. For 10,866
participants (98.3%) who provided fasting (8 h) blood samples, we also
evaluated the association of fasting glucose levels and incident heart failure by
using clinical categories of glucose concentration as follows: 5.0, 5.0–5.5,
5.6–6.0, 6.1–6.9 mmol/l (90, 90–99, 100–109, and 110–125 mg/dl). We used the
most prevalent category within a normal range as a reference group for both A1C
(5.0–5.4%) and fasting glucose (5.0–5.5 mmol/l) levels.
We implemented three models for the adjustment for covariates. Model 1
was adjusted for age, sex, and race. Model 2 was further adjusted for level of
education, carotid atherosclerosis, systolic blood pressure, antihypertensive
medication, smoking, alcohol intake, BMI, LDL cholesterol, HDL cholesterol,
a self-reported history of coronary heart disease (CHD) by visit 2, clinical
examination, or hospital records and estimated glomerular ﬁltration rate.
Model 3 was adjusted for all variables in model 2 plus either baseline fasting
glucose or A1C, as appropriate. We also investigated the association of
quartiles of A1C or fasting glucose with heart failure risk.
We conducted several sensitivity analyses to assess the robustness of our
results. First, we examined heart failure occurring in the absence of clinical CHD.
To accomplish this, we conducted our analysis censoring incident CHD cases that
occurred prior to the date of heart failure (n  1,088). Second, we repeated our
analyses after excluding participants who had incident diabetes in the ﬁrst 6 years
of follow-up (between visit 2 and visit 4) deﬁned by a fasting glucose of 7.0
mmol/l, nonfasting glucose of 11.1 mmol/l, self-reported physician diagnosis of
diabetes, or use of glucose-lowering medication at visit 3 or visit 4 (n600). After
visit 4, the ARIC Study obtained self-reported information on diabetes diagnosis
and medication use by annual telephone calls, for a maximum of 15 years of
follow-up. Using this information, we investigated heart failure occurring in the
absence of diagnosed diabetes by censoring incident diabetes cases occurring
before the heart failure event (n  1,497).
We also examined the association of 1% unit increase in A1C with heart
failure risk. To evaluate whether this association was consistent in groups
with low-/high-risk proﬁle, we evaluated this association in the subgroup of
participants according to the absence/presence of cardiovascular risk factors.
All analyses were conducted using Stata 10.1 software (Stata Corp, College
Station, TX) and a P value of 0.05 was considered statistically signiﬁcant.
RESULTS
Demographic characteristics of participants by categories
of A1C are shown in Table 1. Participants with A1C 5.5%
were more likely to be older, African American, and
smokers but less likely to be current drinkers as compared
with the reference group (A1C 5.0–5.4%). Individuals with
TABLE 1
Characteristics of participants according to categories of A1C
Categories of A1C (%)
3.5–4.9 5.0–5.4 5.5–5.9 6.0–6.4
n 1,012 5,263 3,883 899
Age (years) 55.4  5.5 56.3  5.6 57.4  5.7 58.0  5.6
Male sex (%) 46.8 42.6 44.9 46.1
African American race (%) 15.9 11.8 26.7 50.7
Educational level (%)*
12 years completed 13.4 14.5 23.4 31.9
12–16 years completed 40.4 44.5 40.8 36.6
16 years completed 46.2 41.0 35.8 31.5
Current smokers (%)* 13.0 18.4 29.1 31.3
Current alcohol drinkers (%) 64.3 64.5 56.0 46.1
BMI (kg/m
2)* 26.4  4.7 26.6  4.5 27.8  5.2 29.7  5.9
Fasting glucose (mg/dl)* 97.9  8.4 99.4  8.6 103.4  9.1 108.1  9.7
Antihypertensive medication (%) 23.7 23.5 29.2 42.2
Systolic blood pressure (mmHg)* 118.6  17.4 118.4  18.0 121.6  18.0 125.4  19.5
Diastolic blood pressure (mmHg)* 72.1  10.0 71.5  10.1 72.4  10.3 73.9  10.3
LDL-C (mmol/l)* 3.18  0.91 3.37  0.91 3.54  0.95 3.62  0.96
HDL-C (mmol/l)* 1.37  0.48 1.35  0.45 1.29  0.42 1.22  0.38
Triglycerides (mmol/l)* 1.33  0.77 1.42  0.87 1.46  0.85 1.53  0.87
History of CHD (%) 2.5 3.7 5.0 5.0
Carotid atherosclerosis (%)* 4.4 4.7 6.9 10.1
eGFR (ml/min/1.73 m
2) 86.5  17.6 84.9  16.6 85.7  18.3 87.9  19.6
Data are mean  SD or percentage. All comparisons were signiﬁcant at P  0.001, except for sex (P  0.017). eGFR  estimated glomerular
ﬁltration rate. *Missing values (number missing): educational level, 13; current smokers, 1; BMI 9, fasting glucose 191; blood pressure, 1;
LDL-C, 136: HDL-C, 37; triglycerides, 7; history of CHD, 98; carotid atherosclerosis, 211.
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higher BMI, higher blood pressure, adverse lipid proﬁle,
and higher prevalence of CHD and carotid atherosclerosis.
A1C and fasting glucose were weakly, but signiﬁcantly,
correlated (r  0.32, P  0.001).
During a median follow-up time of 14.1 years, there were
841cases of incident heart failure. The overall incidence
rate of heart failure was 5.7 per 1,000 person-years. The
continuous associations of A1C and fasting glucose levels
with incidence rate of heart failure with the adjustment for
age, sex, and race are shown in Fig. 1. The incidence rate
of heart failure increased linearly above A1C 5.0% (tests
for differences in slopes above A1C 5.0% were not statis-
tically signiﬁcant; data not shown) and was 2-fold or
higher in a range of A1C 6.0% as compared with that of
A1C 5.0%. Although the incidence rate of heart failure
increased at a fasting glucose level of 5.6 mmol/l, the slope
was much shallower than that for A1C and was ﬂat at the
range of 5.0–5.5 mmol/l. Increased risk of heart failure was
observed at the low ranges of A1C (5.0%) and fasting
glucose (5.0 mmol/l), although 95% CIs were wide,
reﬂecting imprecision of the estimate.
We estimated the hazard ratios and corresponding 95%
CIs for incident heart failure by categories of A1C using
Cox proportional hazards models adjusting for multiple
covariates (Table 2). As compared with participants with
A1C 5.0–5.4, the hazard ratios of heart failure rose pro-
gressively from 1.44 (95% CI, 1.24–1.68) to 2.04 (95% CI,
1.63–2.54) across categories of A1C 5.5% in the model
adjusted for age, sex, and race (model 1). The association
among individuals with A1C 6.0–6.4% remained signiﬁcant
even after adjustment for all traditional cardiovascular
risk factors (model 2, hazard ratio 1.38 [95% CI, 1.09–
1.75]), although the association among participants with
A1C 5.5–5.9% was attenuated to borderline signiﬁcance
(hazard ratio 1.16 [0.98–1.36], P  0.08). The adjustment
for fasting glucose did not alter the results (model 3).
These associations did not change appreciably after fur-
ther adjustment for use of antihypertensive drugs (i.e.,
-blockers, ACE inhibitors, or diuretics), which might
potentially affect both glucose metabolism and risk of
heart failure (data not shown).
There was no evidence of effect modiﬁcation by a
history of CHD at baseline (P for interaction  0.83), and
similar, but slightly attenuated, associations were ob-
served when we censored participants without prevalent
CHD at baseline who developed CHD prior to heart failure
(hazard ratio 1.27 [95% CI, 0.95–1.70] for A1C 6.0–6.4% and
trend P  0.095). We obtained similar results even after
further adjusting for insulin levels. The exclusion of par-
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FIG. 1. Incident rates of heart failure (HF) according to A1C and fasting glucose. The graph shows incidence rates (per 1,000 person-years) and
95% CIs (shaded area) of heart failure with spline terms of A1C (knots at 5.0, 5.5, and 6.0%) (A) and fasting glucose (knots at 5.0, 5.6, and 6.1
mmol/l [90, 100, and 110 mg/dl]) (B) adjusted for age, sex, and race. The histograms represent the frequency distribution of A1C (4.5–6.5%) and
fasting glucose (4.2–6.9 mmol/l [75–125 mg/dl]) in the study sample.
TABLE 2
Adjusted hazard ratios (HRs; 95% CI) for incident heart failure (HF) according to A1C categories
Models*
Categories of A1C, range (%)
trend P 5.0 5.0–5.4 5.5–5.9 6.0–6.4
Model 1
No. of cases/subjects 50/1,012 307/5,263 361/3,883 123/899
HR (95% CI) 0.92 (0.68–1.24) Reference 1.44 (1.24–1.68) 2.04 (1.63–2.54) 0.001
Model 2
No. of cases/subjects† 45/970 289/5,078 338/3,707 111/840
HR (95% CI) 0.96 (0.70–1.31) Reference 1.16 (0.98–1.36) 1.38 (1.09–1.75) 0.006
Model 3
No. of cases/subjects‡ 45/955 285/5,002 329/3,642 110/824
HR (95% CI) 0.96 (0.70–1.32) Reference 1.16 (0.98–1.37) 1.40 (1.09–1.79) 0.008
*Model 1: adjusted for age, race, and sex. Model 2: model 1  level of education, carotid atherosclerosis, systolic blood pressure,
antihypertensive medication, smoking, alcohol intake, BMI, LDL-C, HDL-C, a history of CHD at baseline, and eGFR. Model 3: model 2 
fasting glucose. †Participants with all variables used in model 2. ‡Participants with all variables used in model 2 and fasting glucose.
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or censoring participants who self-reported diagnosed
diabetes before heart failure during follow-up did not alter
the results (data not shown).
Participants with fasting glucose levels of 6.1–6.9
mmol/l but not 5.6–6.0 mmol/l had an increased risk of
heart failure as compared with those with glucose levels
of 5.0–5.5 mmol/l in model 1 (Table 3). However, the
association was greatly attenuated after adjustment for
multiple covariates (model 2) and no longer signiﬁcant
when A1C was included in the model (model 3, hazard
ratio 1.11 [95% CI, 0.90–1.35]). By contrast, fasting
glucose 5.0 mmol/l was associated with higher risk of
heart failure as compared with the reference group,
even after adjusted for multiple covariates (model 2,
hazard ratio 1.51 [1.14–2.00]). This association re-
mained signiﬁcant even after adjusting for A1C (model
3) or restricting the sample to participants who contrib-
ute more than 5 years follow-up time (hazard ratio 1.55
[1.13–2.13]). We repeated the analyses using an average
fasting glucose level at visit 1 and visit 2 and obtained
similar results (data not shown).
When we compared the quartiles of A1C and fasting
glucose in model 2, the highest quartile of A1C (5.7–6.4%)
but not fasting glucose (6.0–6.9 mmol/l [108–125 mg/dl])
was associated with heart failure risk as compared with
the lowest quartile of A1C (5.2%) and fasting glucose
(5.3 mmol/l [95 mg/dl]) (hazard ratio 1.42 [1.13–1.78]
and 1.03 [0.84–1.27], respectively). Similar results were
observed when we used the second quartile of fasting
glucose (5.3–5.6 mmol/l [95–100 mg/dl]) as the reference
group (data not shown).
We also examined the joint association of A1C and
fasting glucose with heart failure risk (Table 4). A1C
6.0–6.4% compared with 5.0–5.4% was signiﬁcantly asso-
ciated with increased risk for heart failure at fasting
glucose levels of 5.0–5.5 mmol/l with similar association at
other fasting glucose levels. In contrast, the association of
elevated fasting glucose with heart failure was not signif-
icant at A1C 5.0–5.4%. Similarly, there was no consistent
increase in heart failure risk associated with higher fasting
glucose at other A1C categories. Although the relative risk
associated with higher A1C tended to be larger among
participants with low/normal fasting glucose levels as
compared with those with elevated fasting glucose levels,
the interaction of A1C and fasting glucose categories on
heart failure risk was not signiﬁcant (P  0.257).
Finally, we modeled the association of heart failure
risk per 1% unit increase in A1C and examined this
association in different subgroups (Fig. 2). Overall, each
1% unit increase in A1C was associated with 39% (95%
CI, 13–70%) increased risk of heart failure after adjusted
for multiple covariates. These results were largely con-
sistent across the different subpopulations (all Ps for
interaction 0.05).
TABLE 3
Adjusted HRs (95% CI) for incident HF according to fasting glucose categories
Models*
Categories of fasting glucose, range (mmol/l)
trend P 5.0 5.0–5.5 5.6–6.0 6.1–6.9
Model 1
No. of cases/subjects 67/977 238/3,864 301/3,949 219/2,076
HR (95% CI) 1.27 (0.97–1.66) Reference 1.13 (0.95–1.34) 1.49 (1.23–1.79) 0.001
Model 2
No. of cases/subjects† 64/942 221/3,728 280/3,789 204/1,964
HR (95% CI) 1.51 (1.14–2.00) Reference 1.04 (0.87–1.24) 1.19 (0.98–1.45) 0.743
Model 3
No. of cases/subjects† 64/942 221/3,728 280/3,789 204/1,964
HR (95% CI) 1.54 (1.16–2.04) Reference 1.00 (0.84–1.20) 1.11 (0.90–1.35) 0.609
*Model 1: adjusted for age, race, and sex. Model 2: model 1  level of education, carotid atherosclerosis, systolic blood pressure,
antihypertensive medication, smoking, alcohol intake, BMI, LDL-C, HDL-C, a history of CHD at baseline, and eGFR. Model 3: model 2  A1C.
†Participants with all variables used in model 2.
TABLE 4
Adjusted* HRs (95% CI) for incident HF according to the combination of A1C and fasting glucose categories
Categories of fasting
glucose, mmol/l
Categories of A1C, %
5.0 5.0–5.4 5.5–5.9 6.0–6.4
5.0
No. of cases/subjects 10/151 29/576 22/212 5/26
HR (95% CI) 1.99 (1.04–3.81) 1.42 (0.94–2.15) 1.75 (1.10–2.79) 3.57 (1.45–8.79)
5.0–5.5
No. of cases/subjects 15/444 104/2,151 83/1,075 25/131
HR (95% CI) 0.83 (0.49–1.44) Reference 1.18 (0.88–1.58) 2.19 (1.40–3.43)
5.6–6.0
No. of cases/subjects 17/288 108/1,736 126/1,499 32/312
HR (95% CI) 1.15 (0.68–1.92) 1.11 (0.85–1.45) 1.16 (0.89–1.51) 1.29 (0.86–1.94)
6.1–6.9
No. of cases/subjects 3/87 48/615 107/921 49/371
HR (95% CI) 0.62 (0.20–1.96) 1.20 (0.85–1.70) 1.44 (1.09–1.90) 1.38 (0.97–1.96)
*Adjusted for age, race, and sex, level of education, carotid atherosclerosis, systolic blood pressure, antihypertensive medication, smoking,
alcohol intake, BMI, LDL-C, HDL-C, a history of CHD at baseline, and eGFR.
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In this community-based population, we found that ele-
vated A1C even in the range under 6.5% was associated
with heart failure risk independently of traditional cardio-
vascular risk factors in middle-aged individuals during a
median of 14 years of follow-up. The risk conferred by 1%
unit increase in A1C in our study was 39% and was slightly
higher than what has been reported in populations of
people with diabetes (3–6). This association remained
signiﬁcant even after censoring participants who devel-
oped diabetes during median follow-up of 14 years before
incident heart failure, suggesting that impaired glucose
metabolism even before the development of diabetes is an
independent risk factor of heart failure.
Given that the association between A1C and heart
failure risk was somewhat attenuated by limiting to heart
failure cases without preceding CHD, elevated A1C appar-
ently confers heart failure risk partially through its asso-
ciation with increased CHD risk (22). Several other
mechanisms might explain the positive association be-
tween A1C and risk of heart failure. People with glucose
intolerance may have other comorbidities like hyperten-
sion or obesity predisposing to the development of heart
failure (23). Hyperinsulinemia may also play a role by
stimulating sodium retention and/or activating the sympa-
thetic nervous system (8). Insulin is a known growth factor
and may contribute to myocardial dysfunction via in-
creases in cardiac mass (8). However, the association of
A1C with risk of heart failure in our study was indepen-
dent of hypertension, obesity, other traditional cardiovas-
cular risk factors, and insulin concentration, suggesting
direct effects of hyperglycemia on the development of
heart failure. Indeed, hyperglycemia may harm the heart
via oxidative stress (7,24). Increased oxidative stress is
associated with cell injury or apoptosis, resulting in de-
creased cardiac contractile (24). Glucose may also interact
with collagen and stimulate the production of advanced
glycation end products (25). Advanced glycation end prod-
ucts are hypothesized to induce ﬁbrosis in the heart,
leading to myocardial stiffness and diastolic dysfunction
(25,26).
Whether lowering A1C via lifestyle modiﬁcation or
medication can reduce the risk of heart failure in nondia-
betic populations is an important question. To our knowl-
edge, no study has speciﬁcally investigated this issue.
Some clinical trials (27,28), but not all (29), demonstrated
that interventions with lifestyle modiﬁcation or glucose-
lowering medications may reduce cardiovascular risk in
individuals with impaired glucose tolerance. The STOP-
NIDDM Trial showed reduced risk of cardiovascular
events by an -glucosidase inhibitor, acarbose, but had
few heart failure cases (27). Although an increased risk of
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FIG. 2. Hazard ratios (HRs) of heart failure per 1% unit increase in A1C. Hazard ratios overall and within subgroups adjusted for the same
covariates as model 2 in Table 2 are shown. Error bars represent 95% CIs. eGFR  estimated glomerular ﬁltration rate.
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the DREAM Trial (29), the elevated risk of heart failure
may be speciﬁc to this pharmacologic agent (30). Further
studies are needed to evaluate whether early interventions
to prevent glucose intolerance and lower A1C levels might
reduce subsequent heart failure risk.
In contrast to the robust independent association of A1C
with increased risk of heart failure, fasting glucose was
only weakly associated and no longer signiﬁcant after
adjusting for A1C in our study population. This weak
association between fasting glucose and incident heart
failure in a nondiabetic population is consistent with the
previous literature (7,8) and may result from relatively
high variability in glucose measurements (9). Superiority
of A1C to fasting glucose for disease prediction has also
been observed for CHD, stroke, and total mortality (31).
Nevertheless, our results suggest that A1C is a better risk
marker of heart failure as compared with fasting glucose
in a nondiabetic population.
Participants with a fasting glucose 5.0 mmol/l had an
increased risk of heart failure compared with individuals
with fasting glucose 5.0–5.5 mmol/l in our study. Such a
J-shaped association has been observed for all-cause or
cardiovascular mortality in some studies (32–34) but not
for heart failure (7,8,35). Given that excluding heart failure
cases within 5 years of follow-up did not alter our ﬁndings,
reverse causation is unlikely. There remains the possibility
that comorbid conditions associated with both lower
glucose concentration and risk of heart failure, e.g., liver
dysfunction (36), might account for the observed higher
heart failure risk at low serum glucose concentrations.
Several limitations of the present study should be men-
tioned. First, we evaluated the association of a single
measurement of A1C and heart failure. A previous study
showed that updated average A1C may predict future
heart failure better than a single baseline A1C in patients
with diabetes (4). However, in nondiabetic populations, a
single A1C measurement is highly reliable (37,38). Second,
as with any observational study, we cannot rule out the
possibility of residual confounding despite adjustment for
all major cardiovascular risk factors. Third, identiﬁcation
of heart failure cases relied entirely on ICD codes ab-
stracted from hospital records and death certiﬁcates
(6,39). Reliance on hospital discharge codes may underes-
timate heart failure incidence (40). Finally, because the
ARIC Study consists of a middle-aged, bi-ethnic commu-
nity-based population of the U.S., additional studies are
needed in younger populations, the elderly, or other
ethnicities.
In conclusion, elevated A1C (5.5–6.0%) was more
strongly associated with increased risk of heart failure as
compared with fasting glucose in a middle-aged bi-ethnic
population without diabetes. Our ﬁndings suggest that
chronic hyperglycemia even before the development of
diabetes is an independent risk factor of heart failure and
may contribute to the development of heart failure beyond
its effect on CHD risk.
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